We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

136 hedge funds and large institutions have $262M invested in Amylyx Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 16

61% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 31

39% more capital invested

Capital invested by funds: $188M → $262M (+$73.3M)

11% more funds holding

Funds holding: 122 → 136 (+14)

10.73% more ownership

Funds ownership: 72.67% → 83.41% (+11%)

14% less call options, than puts

Call options by funds: $524K | Put options by funds: $606K

Holders
136
Holders Change
+14
Holders Change %
+11.48%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
32
Increased
50
Reduced
31
Closed
16
Calls
$524K
Puts
$606K
Net Calls
-$82K
Net Calls Change
+$497K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$20.3M
2
Millennium Management
Millennium Management
New York
+$8.85M
3
GPP
Great Point Partners
Connecticut
+$6.45M
4
WP
Woodline Partners
California
+$5.73M
5
SVCM
Saturn V Capital Management
Texas
+$5.47M

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$5.81M
2
Jane Street
Jane Street
New York
-$1.55M
3
CSS
Cubist Systematic Strategies
Connecticut
-$1.39M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.32M
5
Walleye Capital
Walleye Capital
New York
-$953K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$2.81M -$5.81M -1,631,909 -67%
Two Sigma Investments
27
Two Sigma Investments
New York
$2.7M +$393K +110,536 +17%
Alyeska Investment Group
28
Alyeska Investment Group
Illinois
$2.66M -$260K -73,008 -9%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$2.3M +$1.45M +408,400 +169%
Deutsche Bank
30
Deutsche Bank
Germany
$2.02M – – –
Renaissance Technologies
31
Renaissance Technologies
New York
$1.82M +$180K +50,700 +11%
Morgan Stanley
32
Morgan Stanley
New York
$1.68M +$36.3K +10,198 +2%
Citigroup
33
Citigroup
New York
$1.64M -$520K -146,084 -24%
Charles Schwab
34
Charles Schwab
California
$1.32M +$263K +73,904 +25%
O
35
OrbiMed
New York
$1.23M – – –
RSCM
36
Rock Springs Capital Management
Maryland
$1.22M +$1.22M +343,228 New
Jane Street
37
Jane Street
New York
$1.17M -$1.55M -434,290 -57%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.03M +$288K +80,974 +39%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$956K -$131K -36,738 -12%
AI
40
Allostery Investments
Connecticut
$942K +$947K +266,099 New
State Street
41
State Street
Massachusetts
$927K +$154K +43,400 +20%
AC
42
Aldebaran Capital
Indiana
$918K -$12.5K -3,500 -1%
Walleye Capital
43
Walleye Capital
New York
$888K -$953K -267,896 -52%
Marshall Wace
44
Marshall Wace
United Kingdom
$875K +$223K +62,597 +34%
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
$855K -$1.32M -369,819 -60%
Federated Hermes
46
Federated Hermes
Pennsylvania
$718K +$1.67K +469 +0.2%
KCM
47
Kennondale Capital Management
Virginia
$718K +$243K +68,298 +51%
AWG
48
Alpha Wave Global
New York
$663K +$138K +38,684 +26%
OAC
49
OMERS Administration Corp
Ontario, Canada
$600K +$369K +103,600 +157%
BCM
50
Bridgeway Capital Management
Texas
$551K +$32.7K +9,200 +6%
1
2
3 4 5

AMLX Hedge Fund Activity: Q1 2025 in Review

136 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2025, worth a combined $262M — up 39% from $188M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new AMLX positions and 16 closed out — a net gain of 16 holders — while 50 added to existing stakes and 31 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $20.3M. The largest seller was Bank of America, cutting an estimated $5.81M.

  • 136 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2025, up from 122 in Q4 2024.
  • Funds reported $262M of Amylyx Pharmaceuticals stock for Q1 2025, up 39% quarter-over-quarter.
  • 32 funds opened new Amylyx Pharmaceuticals positions in Q1 2025 and 16 closed out, a net change of +16 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2025 was Adage Capital Partners, an estimated $20.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2025 was Bank of America, an estimated $5.81M sold.

Based on aggregated 13F filings for Q1 2025.